A Prescription Is Only the Beginning
U.S. access to buprenorphine—the medication used to treat opioid use disorder—is the subject of this series. The central question is narrower and more practical than whether the country has more clinicians who can prescribe it: can a person who needs treatment obtain the next dose on time and continue taking it? That distinction supports a better judgment about access. A prescription is a necessary start, but it is not yet treatment in the patient's hands.
Buprenorphine is an FDA-approved, first-line medication for opioid use disorder, or OUD. OUD is a medical condition in which opioid use becomes difficult to control despite harmful consequences. The study describes buprenorphine as a first-line treatment that reduces opioid-overdose mortality; the point is not simply to make a prescription available, but to make treatment usable and continuous. When a patient cannot fill a prescription, the interruption is not an administrative footnote. It can leave them without a medication that was intended to stabilize care at exactly the moment when continuity matters.
Continuity is not the same as taking a drug forever or following one fixed schedule. It means that a patient who and their clinician have decided to continue treatment can obtain the medication reliably enough for the treatment plan to function. A short delay may be manageable for one person and disruptive for another. A longer gap can require a new search for a pharmacy, another call to a prescriber, an insurance appeal, or a return visit. The important point is that the clinical value of buprenorphine depends partly on a delivery system outside the exam room. A clinician can make a sound decision and still be unable to complete the treatment pathway if the prescription stalls downstream.
That is why a familiar policy story is incomplete. Telemedicine can connect patients with clinicians without requiring every visit to happen in person. Changes in prescribing rules can widen the pool of professionals able to offer medication treatment. These changes address real barriers, including travel, scheduling, stigma, and a shortage of nearby clinicians. But they act at the upstream end of the system. They make it more possible for a prescription to be written. They do not, by themselves, ensure that a pharmacy has buprenorphine in stock, can order it quickly, accepts the prescription, resolves an insurance problem, or feels able to dispense it.
There is also a systems reason not to assume that upstream expansion will automatically produce a downstream result. If more patients can reach a prescriber, more prescriptions may arrive at pharmacies that already have limited stock, cautious ordering practices, or complicated payment processes. That possibility is a logical implication of the chain, not a causal estimate established by the sources here. It tells us what to inspect: whether the pharmacy link has the capacity and rules needed to absorb the additional demand. Counting clinicians at the entrance cannot answer that question by itself.
The subject, then, is not “access” as an undifferentiated promise. It is the reliability of a chain that links clinical capacity to a patient's next dose.
The number of prescriptions is an important but incomplete signal
The CDC's Buprenorphine Dispensing Rate Maps provide a useful view of one part of that chain. The page reports that the national rate remained relatively stable from 2019 through 2024 and reached 4.5 buprenorphine prescriptions per 100 people in 2024, or more than 15 million prescriptions. It also shows wide differences among states: the listed 2024 rate was 24.9 per 100 people in West Virginia and 1.2 in Iowa. Those figures make an important fact visible: dispensing activity is not distributed evenly across the country.
But “4.5 prescriptions per 100 people” does not mean that 4.5 people received a full course of treatment, or that a patient who received one prescription could refill the next one without delay. It is an annual rate of estimated retail pharmacy dispensing. A prescription may be new or refilled; the measure counts activity in a pharmacy system, not a continuous treatment relationship. The map is therefore valuable for showing patterns at the population level, while being silent about the last mile of an individual encounter.
The denominator matters as much as the headline. The CDC describes an estimate of retail pharmacy-dispensed prescriptions per 100 persons per year, using projected prescription totals and resident population. That is a sensible way to compare broad dispensing activity across states, but it is not a direct measure of the number of patients in treatment. One patient may account for several prescriptions, while another may receive a prescription that is never filled or is filled only after a delay. An annual population denominator also cannot tell us whether access was timely for the person who needed medication this week.
The same caution applies to state comparisons. A high dispensing rate can reflect many overlapping conditions: prescribing practices, need for treatment, insurance arrangements, pharmacy participation, refill patterns, or other local features. A low rate can indicate limited treatment capacity, barriers to obtaining medication, lower recorded retail dispensing, or a combination of factors. The map does not identify which link produced the difference. It does not show how long a patient waited, whether a pharmacy had to order the medication, whether a claim was rejected, or whether treatment continued after the prescription was dispensed.
This is not a weakness that makes the map useless. It is a boundary that tells us what question to ask next. If annual dispensing is an upstream signal, reliable access requires evidence about the transaction that follows: whether the prescription could be filled, how quickly, and whether the patient went without medication while the problem was being resolved.
Why prescribing capacity does not settle the access question
It helps to follow a prescription as a sequence rather than imagining it as a single event. A clinician evaluates a patient and issues an order. A pharmacy receives that order and must decide whether it can dispense it. That decision depends partly on inventory: the medication may be available, may need to be ordered, or may be subject to an ordering limit or backorder. It can depend on payment: coverage rules, prior authorization, or noncoverage may stand between an approved prescription and a paid claim. It can also depend on professional judgment and institutional policy, especially when a prescription comes from a telemedicine clinician whose physical distance from the pharmacy is interpreted as a possible diversion risk.
Only after those steps does the patient receive the medication. If any step takes long enough, the outcome is not merely “a prescription was written but processed later.” The patient may have days without buprenorphine. A chain can therefore have substantial capacity at its first link and still be unreliable at its point of use.
The distinction also prevents a misleading view of pharmacy behavior. A pharmacy that needs to order medication is not necessarily refusing care, and a pharmacist's question is not proof that a patient is doing anything wrong. The problem can arise from how controlled substances are monitored, how wholesalers and pharmacies manage ordering, how insurers authorize payment, or how policies interpret a remote prescriber. These mechanisms can produce the same patient-facing result—a delayed fill—while requiring different remedies. Adding clinicians will not solve a stock or payment bottleneck unless the downstream system can absorb the additional prescriptions.
Geography complicates the chain without reducing it to a rural-versus-urban story. Someone in a rural area may have fewer nearby pharmacies, longer travel times, or less transportation, so a delay at one pharmacy can be harder to work around. Yet a pharmacy-level barrier can affect people in nonrural places too, particularly when the issue is stock, insurance, or hesitation about telemedicine rather than physical distance. The relevant question is not simply where the patient lives. It is which link failed, how many alternatives were available, and how long the patient had to wait.
This model also changes what “success” should mean. A system can write more prescriptions, dispense more prescriptions over a year, and still leave a meaningful number of patients waiting at the counter. Conversely, a difficult fill may eventually be resolved without showing up as a permanent failure in an annual dispensing total. Those statements are not contradictory because they describe different points in time and different units of analysis. Reliable access asks whether the patient received the intended medication with enough continuity for care to work, not only whether the system recorded a transaction somewhere in the year.
This is the practical model to carry forward:
The arrows are not a claim that every prescription follows one identical path. They are a way to keep separate questions separate. Prescribing capacity asks whether a clinician can offer treatment. Dispensing activity asks whether prescriptions are being recorded through retail pharmacies. Fill reliability asks whether a particular order reaches the patient without undue delay. Continuity asks whether the patient can keep receiving medication over time. Evidence at one level cannot simply be substituted for evidence at another.
The question that follows
The CDC map establishes why the national picture cannot be reduced to a single average. The access chain explains why a large number of prescriptions cannot, on its own, prove that treatment is reliable. The next question is how these downstream mechanisms appear in patients' experiences: how often pharmacies need to order buprenorphine, how often insurance or telemedicine concerns interfere, how many days patients go without medication, and whether rural residence explains the pattern.
That sequence keeps the subject in view. The issue is not whether prescribing expansion has value; it can remove real barriers to reaching a clinician. The issue is whether the rest of the system is prepared to convert that potential into timely, continuous treatment. More prescribers may enlarge the entrance to care. They do not guarantee that the medication will be waiting at the other end.